Poor
Needs Fix
Patient Risk:
Moderate
Summary
Partially aligned on indication and some mechanistic concepts, but multiple dose, adverse reaction, administration/concomitant use, and NDC/product details are inconsistent or unsupported versus the provided label excerpts.
Category Scores
Accurate Statements
Miebo is a prescription eye drop used to treat the signs and symptoms of dry eye disease.
1 INDICATIONS AND USAGE: "MIEBO (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease (DED)."
Miebo contains perfluorohexyloctane.
11 DESCRIPTION: "...sterile, clear and colorless liquid containing 100% perfluorohexyloctane..."
Miebo works by reducing tear evaporation.
12.1 Mechanism of Action: "Perfluorohexyloctane forms a monolayer at the air-liquid interface of the tear film which can be expected to reduce evaporation."
Blurred vision can be a most common ocular adverse reaction.
6.1 Clinical Trials Experience: "The most common ocular adverse reaction was blurred vision."
Unsupported Statements
The National Drug Code (NDC) for Miebo in a 3 ml bottle in 2023 is 0066-4010-30.
No NDC information was provided in the supplied label excerpts.
Miebo is a novel, non-aqueous hypotonic, and lipid-based formulation.
The supplied label excerpts describe it as "100% perfluorohexyloctane" and provide solubility information, but do not support the specific descriptors "novel, non-aqueous hypotonic, and lipid-based formulation."
Miebo works by stabilizing the tear film.
The mechanism section provided states monolayer formation at the tear film air-liquid interface expected to reduce evaporation; it does not explicitly state "stabilizing the tear film."
Miebo works by spreading across the ocular surface to reduce evaporation from the tear film.
The provided mechanism describes monolayer formation at the air-liquid interface and expected reduction in evaporation; it does not state "spreading across the ocular surface."
The most common side effects reported in clinical trials for Miebo include blurred vision.
While blurred vision is supported as the most common ocular adverse reaction, the claim is phrased as a general "side effects" list; still largely supported. (Kept here only because the prompt asks to evaluate each claim individually and the label provides specific phrasing "ocular adverse reaction" and rates, not a general side effect list.)
Blurred vision from Miebo can occur immediately after instillation.
No timing information (e.g., immediately after instillation) is provided in the supplied label excerpts.
The most common side effects reported in clinical trials for Miebo include eye infections.
The supplied label excerpts do not list eye infections as common adverse reactions.
Miebo is a non-aqueous formulation and should not be administered concomitantly with other eye drops.
The supplied label excerpt does not contain instructions to avoid concomitant eye drops; it only provides guidance to remove contact lenses and an administration schedule for MIEBO itself.
If more than one type of eye drop is needed, Miebo should be administered at least 5 minutes apart from other medications.
No 5-minute separation guidance between MIEBO and other eye drops is provided in the supplied excerpts.
Miebo is manufactured by Bausch + Lomb.
The supplied excerpts state "Distributed by: Bausch & Lomb Americas Inc." but do not state manufacturing responsibility.
Contradictions
High
AI Statement
The recommended dosage for Miebo is one drop in each affected eye twice daily.
Label Reference
2 DOSAGE AND ADMINISTRATION / 2.1 Recommended Dosage: "Instill one drop of MIEBO four times daily into affected eye(s)."
High
AI Statement
Miebo should be dosed approximately 12 hours apart.
Label Reference
2 DOSAGE AND ADMINISTRATION / 2.1 Recommended Dosage: "...four times daily..."
Medium
AI Statement
The most common side effects reported in clinical trials for Miebo include eye infections.
Label Reference
6.1 Clinical Trials Experience: "The most common ocular adverse reaction was blurred vision." (No eye infections reported as most common in the provided excerpt.)
Important Omissions
Recommended dosing frequency (four times daily) and contact lens removal guidance (remove prior to and for at least 30 minutes after administration).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Incorrect dosing frequency/timing claims (twice daily and ~12 hours apart vs label four times daily) and unsupported guidance about avoiding other eye drops may lead to clinically relevant misuse; other discrepancies include unsupported adverse reaction claims (eye infections, immediate blurred vision timing).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Fix
Primary Issue
Dose regimen and related timing are directly contradicted by the label; several other claims (NDC, formulation descriptors, administration separation with other eye drops, eye infection frequency, manufacturing vs distribution) are unsupported by the provided excerpts.
Suggested Improvement
Update dosing to one drop four times daily; remove or qualify any unsupported statements not present in the supplied label excerpts (e.g., NDC, immediate post-instillation timing, eye infections, 5-minute separation, hypotonic/lipid-based descriptors, and manufacturing attribution). Include contact lens removal guidance and adhere strictly to the label's provided administration and adverse reaction statements.